The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Business Of Biotech
Sobernatug: A New Hope for Alzheimer's
This chapter explores the innovative approach of Acumen's lead candidate, Sobernatug, a monoclonal antibody targeting amyloid proteins linked to Alzheimer's disease. It discusses the therapy's unique focus on soluble A-beta oligomers and the transition from intravenous to subcutaneous administration to enhance patient convenience while addressing safety and efficacy concerns. The chapter also emphasizes the importance of biomarkers in early Alzheimer's diagnosis, the financial challenges faced by biotech companies, and the critical need for collaboration in drug development.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
